A Randomized Double-Blind, Placebo-Controlled Trial of Minocycline in Children and Adolescents with Fragile X Syndrome
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Minocycline rescued synaptic abnormalities and improved behavior in the fragile X mouse model. Previous open-label human studies demonstrated benefits in individuals with fragile X syndrome (FXS); however, its efficacy in patients with FXS has not been assessed in a controlled trial. METHOD: Randomized, double-blind, placebo-controlled, crossover trial in individuals with FXS, aged 3.5 years to 16 years (n = 55, mean age 9.2 [SD, 3.6] years). Participants were randomized to minocycline or placebo for 3 months and then switched to the other treatment. RESULTS: Sixty-nine subjects were screened and 66 were randomized. Fifty-five subjects (83.3%) completed at least the first period and 48 (72.7%) completed the full trial. Intention-to-treat analysis demonstrated significantly greater improvements in one primary outcome, Clinical Global Impression Scale-Improvement after minocycline compared with placebo (2.49 ± 0.13 and 2.97 ± 0.13, respectively, p = .0173) and greater improvement in ad hoc analysis of anxiety and mood-related behaviors on the Visual Analog Scale (minocycline: 5.26 cm ± 0.46 cm, placebo: 4.05 cm ± 0.46 cm; p = .0488). Side effects were not significantly different during the minocycline and placebo treatments. No serious adverse events occurred on minocycline. Results may be potentially biased by study design weaknesses, including unblinding of subjects when they completed the study, drug-related side effects unblinding, and preliminary efficacy analysis results known to investigators. CONCLUSIONS: Minocycline treatment for 3 months in children with FXS resulted in greater global improvement than placebo. Treatment for 3 months appears safe; however, longer trials are indicated to further assess benefits, side effects, and factors associated with a clinical response to minocycline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reduction of MMP-9 levels with minocycline in humans with FXS (Dziembowska et al., 2013) contributes to reversal of several FXS phenotypes, including behavioral deficits and enhanced auditory electrocortical activity in adults and/or adolescents with FXS (Paribello et al., 2010; Leigh et al., 2013; Schneider et al., 2013).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Leigh et al., 2013
Experimental — accuracy not yet measuredIn the citing paper
“In a randomized double-blind, placebo-controlled trial in children and adolescents with FXS, three months of minocycline treatment improved anxiety and mood-related behaviours238.”
From Immune mediators in the brain and peripheral tissues in autism spectrum disorder (2015) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wechsler Abbreviated Scale of Intelligence
Dumont, R., Willis, J. O., Veizel, K., & Zibulsky, J. (2014) · Encyclopedia of Special Education · doi:10.1002/9781118660584.ese2519 · Cited by 5,521
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Mullen Scales of Early Learning
Bradley-Johnson, S. (1997) · Psychology in the Schools · doi:10.1002/(sici)1520-6807(199710)34:4<379::aid-pits14>3.0.co;2-e · Cited by 2,325
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072
Stanford-Binet Intelligence Scale
(2012) · SpringerReference · doi:10.1007/springerreference_70151 · Cited by 1,664
Yrjänheikki, J., Tikka, T., Keinänen, R., Goldsteins, G., Chan, P. H., & Koistinaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,038
Dumont, R., & Willis, J. O. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0804 · Cited by 946
de Boer, A. G. E. M., van Lanschot, J. J. B., Stalmeier, P. F. M., van Sandick, J. W., Hulscher, J. B. F., de Haes, J. C. J. M., & Sprangers, M. A. G. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000018499.64574.1f · Cited by 743
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Self-citationBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465
Research works printed but not linked: 1
- Sparrow SS Cicchetti DV Balla DA Vineland Adaptive Behavior Scales 2005 American Guidance Service Circle Pines Second Edition
Cited by
Items 101–200 of 297
Fragile X syndrome and connective tissue dysregulation
Ramírez‐Cheyne, J., Duque, G. A., Ayala‐Zapata, S., Saldarriaga, W., Hagerman, P. J., Hagerman, R. J., & Payán‐Gómez, C. (2018) · Clinical Genetics · doi:10.1111/cge.13469 · Cited by 37
Self-citationDevelopment of mavoglurant and its potential for the treatment of fragile X syndrome
Gomez‐Mancilla, B., Berry‐Kravis, E., Hagerman, R. J., von Raison, F., Apostol, G., Ufer, M., Gasparini, F., & Jacquemont, S. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.857400 · Cited by 33
Self-citationToledo, M. A., Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112068 · Cited by 33
Modelling fragile X syndrome in the laboratory setting: A behavioral perspective
Melancia, F., & Trezza, V. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.04.042 · Cited by 34
Rigoulot, S., Knoth, I. S., Lafontaine, M., Vannasing, P., Major, P., Jacquemont, S., Michaud, J. L., Jerbi, K., & Lippé, S. (2017) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2017.03.008 · Cited by 34
“…that such deficiencies may be at the core of FXS neuropathology, which seems to be confirmed by treatments that rescue synaptic abnormalities and improve behavior in animal models of fragile X syndrome (Leigh et al., 2013) and possibly in patients (Greiss Hess et al., 2016; Utari et al., 2010).”
BackgroundYau, S., Bettio, L. E. B., Vetrici, M. A., Truesdell, A., Chiu, C., Chiu, J., Truesdell, E., & Christie, B. R. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.014 · Cited by 33
“Fragile X Syndrome (FXS) is a genetic disorder and the most common form of inherited intellectual impairment and autism spectrum disorder that can be attributed to a single gene.”
BackgroundInfluentialWhite matter as a monitoring biomarker for neurodevelopmental disorder intervention studies
Swanson, M. R., & Hazlett, H. C. (2019) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-019-9295-8 · Cited by 31
“Clinical trials of other FXS drugs have likewise failed to show improvements in primary endpoints [103], and have been plagued with methodological weaknesses [104] (for a review, see [105]).”
BackgroundThe STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome
Bird, L. M., Ochoa‐Lubinoff, C., Tan, W., Heimer, G., Melmed, R. D., Rakhit, A., Visootsak, J., During, M. J., Holcroft, C., Burdine, R. D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011409 · Cited by 29
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes
Wang, H., Pati, S. B. B., Pozzo‐Miller, L. D., & Doering, L. C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00055 · Cited by 34
“In another randomized, double-blind, placebo-controlled and crossover trial, minocycline treatment administered for 3 months was found to be safe and produce greater global improvement than a placebo in children with fragile X syndrome (Leigh et al., 2013).”
BackgroundThe RNA-binding fragile-X mental retardation protein and its role beyond the brain
Malecki, C., Hambly, B. D., Jeremy, R., & Robertson, E. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00730-4 · Cited by 29
“Minocycline is therefore a promising therapeutic option, with clinical trials showing minocycline treatment in FXS results in improvements in a range of behavioural and neurological deficits (Dziembowska et al. 2013; Leigh et al. 2013; Paribello et al. 2010; Siller and Broadie 2012).”
BackgroundImpact of maternal immune activation on dendritic spine development
Pękała, M., Doliwa, M., & Kalita, K. B. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22804 · Cited by 28
State‐of‐the‐art therapies for fragile X syndrome
Protic, D. D., & Hagerman, R. J. (2024) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15885 · Cited by 26
Self-citationDevelopment of global rating instruments for pediatric patients with ataxia telangiectasia
Nissenkorn, A., Borgohain, R., Micheli, R., Leuzzi, V., Hegde, A. U., Kandadai, R. M., Molinaro, A., D’Agnano, D., Yareeda, S., & Ben‐Zeev, B. (2015) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2015.09.002 · Cited by 26
Pellerin, D., Lortie, A., & Corbin, F. (2017) · Platelets · doi:10.1080/09537104.2017.1317733 · Cited by 25
Hodges, S. L., Nolan, S. O., Taube, J. H., & Lugo, J. N. (2017) · Neuroreport · doi:10.1097/wnr.0000000000000905 · Cited by 27
An “Omic” Overview of Fragile X Syndrome
Dionne, O., & Corbin, F. (2021) · Biology · doi:10.3390/biology10050433 · Cited by 25
“During clinical trials, minocycline mildly improved FXS patient’s behavior, with a more pronounced effect on irritability and anxiety [142,143].”
BackgroundShaffer, R. C., Reisinger, D. L., Schmitt, L., Lamy, M., Dominick, K. C., Smith, E. G., Coffman, M. C., & Esbensen, A. J. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.06.020 · Cited by 25
The neurobiology of the Prader-Willi phenotype of fragile X syndrome
Muzar, Z., Lozano, R., Kolevzon, A., & Hagerman, R. J. (2016) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2016.01082 · Cited by 22
“Minocycline has been studied in children with FXS and has demonstrated some efficacy so it is often utilized clinically (35,36).”
BackgroundSelf-citationMechler, K., Häge, A., Schweinfurth, N., Glennon, J. C., Dijkhuizen, R. M., Murphy, D., Durston, S., Williams, S., Buitelaar, J. K., Banaschewski, T., et al. (2017) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000546 · Cited by 24
“Ratings on the CGI-I scale diff ered statistically signifi cantly between groups in favour of the treat-ment group (Leigh et al., 2013).”
InfluentialPerson‐Oriented Research Ethics to Address the Needs of Participants on the Autism Spectrum
Cascio, M. A., Weiss, J. A., & Racine, É. (2020) · Ethics & Human Research · doi:10.1002/eahr.500064 · Cited by 25
Fragile X syndrome clinical trials: exploring parental decision‐making
D'Amanda, C. S., Peay, H. L., Wheeler, A., Turbitt, E., & Biesecker, B. B. (2019) · Journal of Intellectual Disability Research · doi:10.1111/jir.12605 · Cited by 21
Reconnoitering the transformative journey of minocycline from an antibiotic to an antiepileptic drug
Singh, T., Thapliyal, S., Bhatia, S., Singh, V., Singh, M., Singh, H. B., Kumar, A., & Mishra, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120346 · Cited by 21
Chronic minocycline treatment improves social recognition memory in adult male Fmr1 knockout mice
Yau, S., Chiu, C., Vetrici, M. A., & Christie, B. R. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.015 · Cited by 21
Pharmacological therapies for Angelman syndrome
Tan, W., & Bird, L. M. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-015-0408-z · Cited by 22
Ruíz‐Antorán, B., Sancho‐López, A., Cazorla-Calleja, R., López-Pájaro, L. F., Leiva, Á., Escalera, G. I., Marín-Serrano, M. E., Rincón-Ortega, M., Herguedas, J. L., Rossignoli-Palomeque, T., et al. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0891-6 · Cited by 20
Berry‐Kravis, E. (2022) · Journal of Child Neurology · doi:10.1177/08830738221089740 · Cited by 20
Fragile X Syndrome: Prevalence, Treatment, and Prevention in China
Niu, M., Han, Y., Dy, A. B. C., Du, J., Jin, H., Qin, J., Zhang, J., Li, Q., & Hagerman, R. J. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00254 · Cited by 22
“(26) conducted a controlled trial to confirm the efficacy of minocycline in 55 FXS patients ranging from 3.”
MethodSelf-citationLozano, R., Martínez‐Cerdeño, V., & Hagerman, R. J. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150914121038 · Cited by 23
“These advances in understanding the neurobiology of FXS have led to studies of targeted treatments that can rescue many features of FXS in the Fmr1 KO mice and in other animal models [22, 29-33].”
Self-citationColvin, S. M., & Kwan, K. Y. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00239 · Cited by 19
Shilts, J., & Broadie, K. S. (2017) · Journal of Cell Science · doi:10.1242/jcs.200808 · Cited by 17
“, 2009; Siller and Broadie, 2011, 2012), and has shown promise in clinical trials for human patients (Leigh et al., 2013), showing that elevated Mmp activity is causally linked to FXS neuropathology (Doll and Broadie, 2014).”
BackgroundChampigny, C., Morin-Parent, F., Bellehumeur-Lefebvre, L., Çaku, A., Lepage, J.-F., & Corbin, F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.762967 · Cited by 16
“Security In fact, as previously reported in monotherapy trials (15, 16, 23, 24), most adverse events following lovastatin or minocycline administration were mild, self-limited, and poorly related to treatment with the exception of CK elevation.”
Translational endpoints in fragile X syndrome
de Esch, C. E. F., Zeidler, S., & Willemsen, R. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.012 · Cited by 19
Roberts, M. C. (2019) · Wiley eBooks · doi:10.1002/9781119593522.ch5 · Cited by 17
Weisz, E. D., Monyak, R. E., & Jongens, T. A. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.05.015 · Cited by 16
Behavioral Problems in Fragile X Syndrome: A Review of Clinical Management
Davidson, M., Sebastian, S. A., Benitez, Y., Desai, S., Quinonez, J., Ruxmohan, S., Stein, J. D., & Cueva, W. (2022) · Cureus · doi:10.7759/cureus.21840 · Cited by 22
“In addition to diarrhea, other adverse effects were dizziness and seroconversion to a positive antinuclear antibody (ANA) in two participants [11,36].”
BackgroundThe quest for targeted therapy in fragile X syndrome
Zeidler, S., Hukema, R. K., & Willemsen, R. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1079176 · Cited by 16
New Therapeutic Options for Fragile X Syndrome
Jalnapurkar, I. R., Cochran, D., & Frazier, J. A. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0551-8 · Cited by 15
Targeted treatments in fragile X syndrome
Hare, E. B., Hagerman, R. J., & Lozano, R. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.903795 · Cited by 15
“Side effects were not significantly different during the minocycline and placebo treatment periods [80].”
BackgroundSelf-citationde Diego‐Otero, Y., Medina, R. C., Quintero-Navarro, C., Salido, L. S., García-Guirado, F., del Arco, I., Fernández-Carvajal, I., Ferrando-Lucas, T., Caballero‐Andaluz, R., & Pérez-Costillas, L. (2014) · Trials · doi:10.1186/1745-6215-15-345 · Cited by 18
“NCT01053156 Phase II single centre Minocycline Adolescents and children Antibiotic Completed University of California, Davis (USA) [65]”
BackgroundD’Antoni, S., Spatuzza, M., Bonaccorso, C. M., & Catania, M. V. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105731 · Cited by 13
“…is a well-tolerated drug and exerts positive effects on behavioural symptoms, including social interaction deficits and repetitive behavior, in FXS patients (Paribello et al., 2010; Leigh et al., 2013; for a review on FXS proposed treatments and clinical trials see Johnson et al., 2023).”
Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon
Hagerman, R. J., & Hagerman, P. J. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-090147 · Cited by 15
Self-citationFreitag, C. M., & Jarczok, T. A. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_13 · Cited by 13
The quest for fragile X biomarkers
Westmark, C. J. (2014) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-014-0001-3 · Cited by 12
“Minocycline also prevents all neuroanatomical defects in FXS flies and improves language and social communication skills, anxiety, attention, irritability, stereotypy, hyperactivity and inappropriate speech in humans [15-17].”
BackgroundFRAGILE X SYNDROME AND PREMUTATION‐ASSOCIATED DISORDERS
Hagerman, R. J. (2020) · Wiley eBooks · doi:10.1002/9781119432692.ch28 · Cited by 12
Self-citationBlood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome
Jasoliya, M., Bowling, H. L., Petrasic, I. C., Durbin-Johnson, B. P., Klann, E., Bhattacharya, A., Hagerman, R. J., & Tassone, F. (2020) · Brain Sciences · doi:10.3390/brainsci10060361 · Cited by 12
Self-citationEffects of a social stimulus on gene expression in a mouse model of fragile X syndrome
Rogers, T. D., Anacker, A. M. J., Kerr, T. M., Forsberg, C. G., Wang, J., Zhang, B., & Veenstra-VanderWeele, J. M. (2017) · Molecular Autism · doi:10.1186/s13229-017-0148-6 · Cited by 11
Kaczmarek, L. (2018) · Postępy Biochemii · doi:10.18388/pb.2018_119 · Cited by 11
Targeted therapy of cognitive deficits in fragile X syndrome
Puścian, A., Winiarski, M., Borowska, J., Łęski, S., Górkiewicz, T., Chaturvedi, M., Nowicka, K., Wołyniak, M., Chmielewska, J. J., Nikolaev, T., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01527-5 · Cited by 14
“In the case of the FX patients application of minocycline, a drug repeatedly shown to normalize both, MMP-9 levels and behavioral performance in mice [15, 23, 24], turned only partially effective in improving cognitive function and only mildly helped in alleviating anxiety-related symptoms [25, 27, 93, 94].”
BackgroundThe Use of Peptides in the Treatment of Fragile X Syndrome: Challenges and Opportunities
Romagnoli, A., & Marino, D. D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.754485 · Cited by 13
Drosophila melanogaster as a Model to Study Fragile X-Associated Disorders
Trajković, J. Z., Makević, V., Pešić, M., Pavković‐Lučić, S., Milojević, S., Cvjetković, S., Hagerman, R. J., Budimirovic, D. B., & Protic, D. D. (2022) · Genes · doi:10.3390/genes14010087 · Cited by 10
“Examples of this include the minocycline studies in flies that were translated to humans, demonstrating behavioral benefits [100].”
BackgroundSelf-citationTargeted Treatments for Fragile X Syndrome
Johnson, D., Clark, C. J., & Hagerman, R. J. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-21054-9_10 · Cited by 10
Self-citationThe mGluR Theory of Fragile X: From Mice to Men
Stoppel, L. J., Osterweil, E. K., & Bear, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00009-3 · Cited by 14
Intellectual Disabilities and Global Developmental Delay
Pinchefsky, E. F., & Shevell, M. I. (2017) · Springer eBooks · doi:10.1007/978-3-319-57196-6_2 · Cited by 11
Reading in Children With Fragile X Syndrome: Phonological Awareness and Feasibility of Intervention
Adlof, S. M., Klusek, J., Hoffmann, A., Chitwood, K. L., Brazendale, A. B., Riley, K., Abbeduto, L., & Roberts, J. E. (2018) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-123.3.193 · Cited by 10
“The SB5 is an individually administered assessment of intelligence and cognitive abilities, normed for individuals aged 2 through 85+ years, and it has been used frequently with the FXS population (Berry-Kravis, Sumis, Hervey, & Mathur, 2012; Leigh et al., 2013).”
MethodClinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
Laroui, A., Galarneau, L., Abolghasemi, A., Benachenhou, S., Plantefève, R., Bouchouirab, F. Z., Lepage, J., Corbin, F., & Çaku, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-19476-y · Cited by 11
Fragile X Syndrome and Targeted Treatments
Tassanakijpanich, N., Cabal-Herrera, A. M., Salcedo‐Arellano, M. J., & Hagerman, R. J. (2020) · Journal of Biomedicine and Translational Research · doi:10.14710/jbtr.v6i1.7321 · Cited by 10
Self-citationBudimirovic, D. B., & Duy, P. Q. (2015) · Engrami · doi:10.5937/engrami1504005b · Cited by 10
Erickson, C. A., Shaffer, R. C., Will, M., Schmitt, L., Horn, P. S., Hirst, K., Pedapati, E. V., Ober, N., Tumuluru, R. V., Handen, B. L., et al. (2023) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-023-06132-1 · Cited by 10
“Fifty-five youth with FXS (age range 3.5–16 years; mean age 9.2 years) participated in a 12-week, double-blind placebo-controlled crossover trial of minocycline (dose range 25 mg to 100 mg per day based on weight) (Leigh et al., 2013).”
InfluentialSaldaris, J. M., Ayalde, J., Kankanange, S., Keeley, J., Leonard, H., Jacoby, P. A., Marsh, E. D., Benke, T. A., Demarest, S., & Downs, J. A. (2024) · International Journal of Language & Communication Disorders · doi:10.1111/1460-6984.13100 · Cited by 9
Harper, K. M., Knapp, D. J., Park, M. A., & Breese, G. R. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.03.007 · Cited by 9
“Though in several long term studies lasting weeks to months using specific patient populations it has been shown to decrease anxiety (Kelly et al., 2015; Leigh et al., 2013).”
BackgroundOxford Handbook of Clinical Specialties
Baldwin, A., Hjelde, N., Goumalatsou, C., & Myers, G. (2016) · doi:10.1093/med/9780198719021.001.0001 · Cited by 9
MMP-9 in Control of Synaptic Plasticity: a Subjective Account
Kaczmarek, L. (2016) · Russian Agency for Digital Standardization · doi:10.20388/omp2016.002.0027 · Cited by 9
Hunt, J. F. V., Li, M., Risgaard, R. D., Ananiev, G. E., Wildman, S. A., Zhang, F., Bugni, T. S., Zhao, X., & Bhattacharyya, A. (2021) · Cells · doi:10.3390/cells11010069 · Cited by 9
Autism spectrum disorder: An omics perspective
Woods, A. G., Wormwood, K. L., Wetie, A. G. N., Aslebagh, R., Crimmins, B. S., Holsen, T. M., & Darie, C. C. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400116 · Cited by 9
“No drug is approved for FXS but clinical trials have been conducted for arbaclofen [82] and minocycline [83, 84] to treat symptoms, with others currently in development [85].”
BackgroundMolecular medicine of fragile X syndrome: based on known molecular mechanisms
Luo, S.-Y., Wu, L., & Duan, R. (2015) · World Journal of Pediatrics · doi:10.1007/s12519-015-0052-0 · Cited by 9
Studying child development in genetic models of ASD
Garg, S., & Green, J. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.009 · Cited by 9
Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT
Deakin, J. F. W., Suckling, J., Dazzan, P., Joyce, E. M., Lawrie, S. M., Upthegrove, R., Husain, N., Chaudhry, I. B., Dunn, G., Jones, P. B., et al. (2019) · Efficacy and Mechanism Evaluation · doi:10.3310/eme06070 · Cited by 10
Matusiak, M., Oziębło, D., Ołdak, M., Rejmak, E., Kaczmarek, L., Skarzynski, P. H., & Skarżyńśki, H. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02732-7 · Cited by 8
Emerging autism and Fragile X syndrome treatments
Parkhill, M., Salmaso, N., D’Angiulli, A., Lee, V., & Aguilar‐Valles, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.02.004 · Cited by 7
Mass Spectrometry for the Study of Autism and Neurodevelopmental Disorders
Wormwood, K. L., Wetie, A. G. N., Ryan, J. P., Darie, C. C., & Woods, A. G. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_28 · Cited by 7
Fragile phagocytes: FMRP positively regulates engulfment activity
Logan, M. A. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201702034 · Cited by 7
“Preliminary human trials also suggest that minocycline improves neurological symptoms in Fragile X syndrome patients (Paribello et al., 2010; Leigh et al., 2013).”
ResultProtic, D. D., Breeze, E., Mendoza‐Morales, G., Zafarullah, M., Abbeduto, L., Hagerman, R. J., Coffey, C. S., Cudkowicz, M., Durbin-Johnson, B. P., Ashwood, P., et al. (2024) · SAGE Open Medicine · doi:10.1177/20503121241282401 · Cited by 8
“Minocycline treatment showed to restore MMP-9 levels to normal levels 41 and, in the FMR1 KO mice, showed to improve dendritic spine maturation, synapse formation, anxiety levels, cognitive performance, and even ultrasonic vocalizations.”
BackgroundSelf-citationAntibiotics and Resistance in the Environment
Roberts, M. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-78538-7_12 · Cited by 9
Intellectual Disability—Concepts, Aetiology, and Genetics
Girimaji, S. C., Basheer, S., Biswas, A. B., & Gangadharan, S. K. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198794585.003.0003 · Cited by 9
Watkins, L. V., Moon, S., Burrows, L., Tromans, S. J., Barwell, J., & Shankar, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2323605 · Cited by 7
Mass Spectrometry for the Study of Autism and Neurodevelopmental Disorders
Wetie, A. G. N., DeKroon, R. M., Mocanu, M., Ryan, J. P., Darie, C. C., & Woods, A. G. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-06068-2_26 · Cited by 6
Oxford Handbook of Clinical Specialties
(2020) · doi:10.1093/med/9780192888501.001.0001 · Cited by 6
McKinney, W. S., Schmitt, L., Stefano, L. A. D., Ethridge, L. E., Norris, J. E., Horn, P. S., Dauterman, S., Rosselot, H., Pedapati, E. V., Reisinger, D. L., et al. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2024.0103 · Cited by 6
“…the Clinical Global Impressions-Improvement (CGI-I) scale in some patients with FXS, but insights into the modi fi ers of treatment response (e.g., age, sex, FMRP expression) are limited (Çaku et al., 2014; Cham-pigny et al., 2021; Leigh et al., 2013; Paribello et al., 2010; Thur-man et al., 2020).”
InfluentialIdentification of a male with fragile X syndrome through newborn screening
Famula, J., Basuta, K., Gane, L. W., Hagerman, R. J., & Tassone, F. (2015) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2015.01031 · Cited by 6
Self-citationSachdeva, A., Jain, P., Gunasekaran, V., Bijarnia‐Mahay, S., Mukherjee, S. B., Hagerman, R. J., Shankar, S. P., Kapoor, S., & Kedia, S. N. (2019) · Indian Pediatrics · doi:10.1007/s13312-019-1504-8 · Cited by 7
Self-citationFreitag, C. M., & Jarczok, T. A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_13 · Cited by 6
Morrill, N. K., Joly‐Amado, A., Li, Q., Prabhudeva, S., Weeber, E. J., & Nash, K. R. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114170 · Cited by 6
Morin‐Parent, F., Champigny, C. M., Cote, S. R., Mohamad, T., Hasani, S. A., Çaku, A., Corbin, F., & Lepage, J. (2024) · Autism Research · doi:10.1002/aur.3222 · Cited by 5
Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome
Munshi, K. R., Pawlowski, K. G., Gonzalez–Heydrich, J., & Picker, J. D. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0200 · Cited by 7
“…adolescents (aged 3.5 to 16 years)with FXS. Treatment for 3 months showed no serious side effects, and global improvement was seen; however, results may be confounded because of early unblinding of subjects, preliminary data analysis, and results being shared with investigators (Leigh et al. 2013).”
InfluentialThe Potential for Proteomics in Understanding Neurodevelopmental Disorders
Wormwood, K. L. (2015) · Journal of Proteomics & Bioinformatics · doi:10.4172/jpb.s5-001 · Cited by 5
“Although no current medications are approved for FXS, clinical trials in humans are currently underway for medications such as arbaclofen [51] and minocycline [52], which address FXS symptoms.”
BackgroundFragile X-Associated Disorders
Lozano, R., Hare, E. B., & Hagerman, R. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00017-6 · Cited by 6
Self-citationOverview of Targeted Double-Blind, Placebo-Controlled Clinical Trials in Fragile X Syndrome
Ligsay, A., Hagerman, R. J., & Berry‐Kravis, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00019-6 · Cited by 4
Self-citationNew Innovations: Therapies for Genetic Conditions
Rajabi, F., & Picker, J. D. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0043-9 · Cited by 5
Are We Ready for Fragile X Newborn Screening Testing?—Lessons Learnt from a Feasibility Study
Wotton, T., Wiley, V. C., Bennetts, B., Christie, L., Wilcken, B. M., Jenkins, G., Rogers, C., Boyle, J., & Field, M. J. (2018) · International Journal of Neonatal Screening · doi:10.3390/ijns4010009 · Cited by 5
“Furthermore, a randomized double-blind, placebo-controlled trial of minocycline in children with FXS resulted in greater global improvement than the placebo [24].”
BackgroundPharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction
Telias, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191102165206 · Cited by 4
Fragile X-Associated Disorders
Summers, S. M., & Hagerman, R. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00008-2 · Cited by 4
Self-citationNeurobiology of Autism Spectrum Disorders
Martins, G. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-42713-3_2 · Cited by 6
Antibiotic-Resistant Environmental Bacteria and Their Role as Reservoirs in Disease
Roberts, M. C. (2017) · Advances in environmental microbiology · doi:10.1007/978-3-319-60616-3_7 · Cited by 4
Neurodevelopmental and Neuropsychiatric Disorders
Monji, A., Maezawa, I., Mizoguchi, Y., Kato, T. A., & Jin, L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1429-6_14 · Cited by 4
Stanfield, A. C., & McKechanie, A. G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2510408 · Cited by 3
“C showed no benefit of minocycline treatment [52].”
InfluentialDrug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome
Scharf, S. H., Gasparini, F., Spooren, W. P. J. M., & Lindemann, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00018-4 · Cited by 3
Hoffmann, A., & Berry‐Kravis, E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800109-7.00020-0 · Cited by 4
MMP-9 plasma level as biomarker of cochlear implantation outcome in cohort study of deaf children
Matusiak, M., Oziębło, D., Ołdak, M., Rejmak, E., Kaczmarek, L., Dobek, D., & Skarżyńśki, H. (2023) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-023-07924-y · Cited by 3
“We suggest, although with extreme caution, that the decrease of MMP-9 levels observed in our clusters might be interpreted in analogy with data on Fragile X syndrome (FXS), a condition associated with cognitive deficits, anxiety, mood imbalance, and increased MMP-9 plasma levels [27].”
ResultMolecular mechanisms for targeted treatments in fragile X syndrome
Miranda, I., & Hagerman, R. J. (2023) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2023.21 · Cited by 3
Self-citationGracia, J., Perumal, D., Dhandapani, P., & Ragunathan, P. T. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128667 · Cited by 3
Metadata
- Authors
- Leigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., Hessl, D., & Hagerman, R. J.
- Affiliations
- University of California Davis Medical Center (US)
- University of California, Davis (US)
- Diponegoro University (ID)
- Corresponding author
- Leigh, Mary Jacena S.
- Schneider, Andrea
- Chechi, Tasleem
- Polussa, Jonathan
- Hessl, David
- Hagerman, Randi J.
- ORCID
- Venue
- Journal of Developmental & Behavioral Pediatrics
- Published
- 2013-04
- Volume
- 34
- Issue
- 3
- Pages
- 147-155
- ISSN
- 0196-206X (ISSN-L)
- PMC
- PMC3706260
- OpenAlex
- W2159857276
- Cited by
- 298
- References
- 37
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 12 · 2023: 7 · 2022: 18 · 2021: 10 · 2020: 48 · 2019: 21 · 2018: 19 · 2017: 35 · 2016: 40 · 2015: 28 · 2014: 32 · 2013: 15
- FWCI
- 25.44
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Developmental & Behavioral Pediatrics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000002)
- University of California, Davis
- National Institute of Mental Health (T32MH073124)
- National Center for Research Resources (UL1RR024146)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD 02274, P30HD002274)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Developmental Neuroscience › Williams Syndrome Research
- Keywords
- minocycline, fragile X syndrome, children and adolescents, anxiety, mood, Clinical Global Impression Scale, treatment efficacy, drug safety, synaptic abnormalities
- MeSH terms
- Adolescent, Child, Child, Preschool, Double-Blind Method, Female, Fragile X Syndrome, Humans, Intelligence, Male, Minocycline, Psychiatric Status Rating Scales, Psychological Tests, Treatment Outcome, Cross-Over Studies, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.